Acquisition of ORIGINAL TOCILIZUMAB SC 162MG/0.9ML SOL, from Lab. Roche, for ULSASI, for the year 2026

This tender concerns the procurement of a specific pharmaceutical product: 'TOCILIZUMAB ORIGINAL SC 162MG/0.9ML SOL'. This medication is to be acquired from the laboratory Roche. The intended recipient and user of this drug is ULSASI (Unidade Local de Saúde do Alto Minho, E.P.E. or similar local health unit). The procurement is specifically for the year 2026. Tocilizumab is a biologic medication used to treat various inflammatory conditions, including rheumatoid arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome. The tender indicates a direct procurement from the original manufacturer, likely to ensure authenticity, quality, and potentially favorable pricing or supply chain security. This acquisition is vital for the provision of necessary medical treatments to patients under the care of ULSASI.

This is a supplies contract in the health and medical services, security and defense and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 14,802.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.